<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025597</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068977</org_study_id>
    <secondary_id>EURO-INF-NB-STUDY-1999-99.1</secondary_id>
    <secondary_id>EU-20125A</secondary_id>
    <nct_id>NCT00025597</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma.</brief_title>
  <official_title>European Infant Neuroblastoma Study - Unresectable Tumors (MYCN Not Amplified)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Infant Neuroblastoma Study Group - 1999</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so
      that it can be removed during surgery.

      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by
      surgery in treating infants who have newly diagnosed neuroblastoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the survival and morbidity of infants with newly diagnosed stage II or III
           unresectable neuroblastoma without MYCN amplification treated with vincristine and
           cyclophosphamide, etoposide and carboplatin, and cyclophosphamide, doxorubicin, and
           vincristine followed by surgery.

        -  Determine whether deletion of chromosome 1p or diploidy/tetraploidy are prognostic
           factors in these patients.

        -  Determine whether there are other prognostic criteria that could be used in future
           therapeutic stratification of these patients.

      OUTLINE: This is a multicenter study. Patients are stratified according to symptomatic spinal
      cord involvement (yes vs no).

      Patients without evidence of symptomatic spinal cord compression receive vincristine IV on
      day 1 and cyclophosphamide IV on days 1-5. Treatment repeats every 14 days for 2 courses.
      Patients eligible for surgery undergo surgical resection and then are removed from the study.

      Patients ineligible for surgery after 2 courses of initial chemotherapy, but with at least
      25% response to initial chemotherapy, receive 2 additional courses of vincristine and
      cyclophosphamide. Patients eligible for surgery undergo surgical resection and then are
      removed from the study.

      Patients ineligible for surgery after 2 additional courses of initial chemotherapy or with
      disease progression receive etoposide IV over 2 hours and carboplatin IV over 1 hour on days
      1-3. Treatment repeats every 21 days for 2 courses. Patients eligible for surgery undergo
      surgical resection and then are removed from the study.

      Patients who remain ineligible for surgery or with disease progression after etoposide and
      carboplatin receive cyclophosphamide IV over 1 hour on days 1-5, doxorubicin IV over 6 hours
      on days 4 and 5, and vincristine IV on days 1 and 5. Treatment repeats every 21 days for 2
      courses. Patients then undergo surgical resection or biopsy.

      Patients with symptomatic spinal cord compression receive initial treatment with etoposide
      and carboplatin as above. Patients with improved symptoms and resectable disease after
      initial chemotherapy undergo surgical resection or biopsy. Patients who remain ineligible for
      surgery or with no improvement in symptoms after initial chemotherapy receive
      cyclophosphamide, doxorubicin, and vincristine as above. Patients then undergo surgical
      resection or biopsy.

      Patients are followed within 6 months and then annually for 5 years.

      PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study within 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1999</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Neuroblastoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed newly diagnosed stage II or III
             neuroblastoma or ganglioneuroblastoma

               -  Unresectable disease

          -  No MYCN amplification (i.e., fewer than 10 copies)

          -  No metastases to bone marrow

          -  No radiological bone lesions in skeleton

        PATIENT CHARACTERISTICS:

        Age:

          -  Under 12 months at diagnosis

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  No evidence of liver disease by ultrasound

        Renal:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herve Rubie, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier Regional de Purpan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Anna Children's Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Ghent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31026</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genoa</city>
        <zip>16148</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rikshospitalet University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues de Oncologia de Francisco Gentil - Centro Regional de Oncologia de Lisboa, S.A.</name>
      <address>
        <city>Lisboa</city>
        <zip>1099-023 Codex</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario LA FE</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ostra Sjukhuset</name>
      <address>
        <city>Gothenburg</city>
        <zip>41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital for Children</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Rubie H, De Bernardi B, Gerrard M, Canete A, Ladenstein R, Couturier J, Ambros P, Munzer C, Pearson AD, Garaventa A, Brock P, Castel V, Valteau-Couanet D, Holmes K, Di Cataldo A, Brichard B, Mosseri V, Marquez C, Plantaz D, Boni L, Michon J. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol. 2011 Feb 1;29(4):449-55. doi: 10.1200/JCO.2010.29.5196. Epub 2010 Dec 20.</citation>
    <PMID>21172879</PMID>
  </results_reference>
  <verification_date>November 2001</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <keyword>localized unresectable neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

